financetom
Business
financetom
/
Business
/
Nasdaq seeks SEC approval for bitcoin index options
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nasdaq seeks SEC approval for bitcoin index options
Aug 27, 2024 3:51 PM

Aug 27 (Reuters) - Nasdaq is seeking the green

light from regulators to launch and trade options on a bitcoin

index, the exchange operator said on Tuesday.

The U.S. Securities and Exchange commission has yet to

approve options based on any of the individual exchange-traded

funds tied to spot bitcoin prices that made their debut in

January, including a Nasdaq application to trade options on

BlackRock's ( BLK ) $21.3-billion iShares Bitcoin Trust ETF

.

The proposed index options - listed derivatives offering a

quick and inexpensive way to amplify exposure to bitcoin - on a

bitcoin index would give institutional investors and traders an

alternative way to hedge their exposure to the world's largest

cryptocurrency.

"It's important for options on bitcoin to be available for

this asset class to be fully normalized," said Matt Hougan,

chief investment officer of Bitwise, one of the group of asset

managers that brought bitcoin ETFs to market this year. "We're

missing a part of the liquidity picture that ETF options would

provide."

Options are listed derivatives that give the holder the

right to buy or sell an asset, such as a stock or

exchange-traded product, at a predetermined price by a set date.

They offer traders a cheap way to amplify their purchasing

power, while institutional investors use them to hedge risk.

The proposed Nasdaq Bitcoin Index Options would track the

CME CF Bitcoin Real-Time Index, developed by CF Benchmarks to

track bitcoin futures and options contracts available on the

exchange operated by CME Group ( CME ), Nasdaq said.

While waiting for regulators to approve or deny options on

the new spot bitcoin ETFs, traders have turned to other

products, such as recently-launched leveraged ETFs tied to

bitcoin and options on those funds.

Exchanges began applying for the spot bitcoin ETF options as

soon as it was clear the SEC would approve the underlying ETFs

in January. But in recent weeks, they have withdrawn and then

refiled those applications in response to SEC comments, said

people familiar with the matter.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Semler Scientific Stock Rallies after Adopting Bitcoin as Treasury Reserve Asset
Semler Scientific Stock Rallies after Adopting Bitcoin as Treasury Reserve Asset
May 28, 2024
01:05 PM EDT, 05/28/2024 (MT Newswires) -- Semler Scientific ( SMLR ) was surging nearly 31% during Tuesday trading after the marketing technology company said it will now use bitcoin as its primary treasury reserve asset after recently buying 581 bitcoins for $40 million. The decision reflects the company's belief that bitcoin is a reliable store of value and a...
Hess investors to vote on Chevron deal amid growing postponement calls
Hess investors to vote on Chevron deal amid growing postponement calls
May 28, 2024
HOUSTON (Reuters) - Hess Corp ( HES ) shareholders will vote on Tuesday on Chevron's ( CVX ) proposed $53 billion acquisition of the company, after many investors have called for a delay in hopes of obtaining a better offer for their shares. The vote has huge implications for both companies. The deal has been stalled in part by a...
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
May 28, 2024
Tuesday, Agios Pharmaceuticals Inc ( AGIO ) agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma Plc ( RPRX ) .  Under the terms of the agreement, Agios will receive an upfront payment of $905 million upon FDA approval of vorasidenib, and Royalty Pharma ( RPRX ) will receive the entirety of the 15% royalty on annual U.S. net sales...
--Street Color: Google Fiber Appoints John Abbot as CFO
--Street Color: Google Fiber Appoints John Abbot as CFO
May 28, 2024
01:05 PM EDT, 05/28/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 177.68, Change: +1.35, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved